Lightstone Ventures, the life sciences-focused progeny of two VC stalwarts, has wrapped up a fund of its own, setting out with $172 million to back early-stage drug and med tech companies.
San Diego's Otonomy has hauled in another $49 million to advance its therapies for ear disorders, hoping to do for hearing-robbing ailments what VEGF inhibitors did for eye diseases.
After shifting its focus to immuno-oncology last year, Germany's Isarna Therapeutics has pulled down $7.6 million to jump-start the development of some preclinical cancer candidates.
Stalwart biotech investor Arch Venture Partners is putting together a $250 million 8th fund, according to a regulatory filing, piling on to the roughly $1.5 billion it currently manages.
A week after the FDA lifted a clinical hold on a trial of its lead cancer candidate, startup Juno Therapeutics has closed its overstuffed $176 million Series A, drawing cash from Arch Venture Partners, Amazon founder Jeff Bezos and others.
Kala Pharmaceuticals, co-founded by MIT biotech luminary Robert Langer, has closed a $22.5 million B round, cash the company says will help advance its novel approach to eye treatments.
A Detroit-based biotech has landed a $59.5 million round to continue its work on a nucleic acid-based DNAi cancer therapy now in a mid-stage trial. ProNAi Therapeutics CEO Mina Sooch says that's enough cash to get the company through 2016, with plans to pursue partnership talks as well as a discussion with the FDA about potential ways to accelerate the approval process for their lead therapy.
Venture investing in the biotech sector hit the $1.1 billion mark in the first quarter of the year--a surprisingly strong showing for what has generally been a quiet season in the U.S. industry.
A biotech startup with roots in Palo Alto, CA has raised $18 million in venture cash to open up a second mid-stage study of its lead therapy, looking to shape a reputation for itself in the lightly populated R&D world of reproductive medicine.
The Column Group has been a busy venture player in the biotech world. And the VC plans to stay busy. In a recent filing at the FDA, the venture group revealed that it has raised close to $176 million out of a planned $250 million fund.